Literature DB >> 16536313

[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors].

Liang-Hong Teng1, De-Hong Lu, Qing-Zhong Xu, Yong-Juan Fu, Hong Yang, Zhi-Li He.   

Abstract

OBJECTIVE: To study the immunohistochemical expression of OCT4, CD117 and CD30 in germ cell tumors and to assess their diagnostic value.
METHODS: Immunohistochemical study for OCT4 was performed on formalin-fixed, paraffin-embedded tissues of 63 cases of germ cell tumors, including seminoma (21), dysgerminoma (7), germinoma (8), embryonal carcinoma (8), yolk sac tumor (6), mature teratoma (10) and immature teratoma (3), as well as 25 cases of non-germ cell tumors, including granulosa cell tumor (8), clear cell adenocarcinoma (4), Leydig's cell tumor (5), diffuse large B-cell lymphoma (4) and malignant melanoma (4). Besides, the expression of CD117 and CD30 in all germ cell tumors was studied.
RESULTS: All cases of seminoma and germinoma, 6/7 cases of dysgerminoma and 7/8 cases of embryonal carcinoma were positive for OCT4, with strong nuclear staining. All other germ cell tumors and non-germ cell tumors were negative for OCT4, except for 1 case of yolk sac tumor and 1 case of clear cell adenocarcinoma which showed weak staining. Positive membranous expression of CD117 was demonstrated in 19/21(90.5%) seminoma, 5/7 dysgerminoma and 7/8 germinoma. Focal weak membranous staining was also noted in 1 case of yolk sac tumor. The melanocytes in teratoma were also positive for CD117. All cases of embryonal carcinoma were negative. On the other hand, positive membranous expression of CD30 were demonstrated in 6/8 embryonal carcinoma. One case of germinoma and 1 case of yolk sac tumor showed weak cytoplasmic positivity. All cases of seminoma and dysgerminoma, 7/8 germinoma and all cases of teratoma were negative for CD30.
CONCLUSIONS: OCT4 is a sensitive and relatively specific marker for diagnosing seminoma, dysgerminoma, germinoma and embryonal carcinoma. CD117 and CD30 immunostains, when used in combination, represent valuable tools for distinguishing embryonal carcinoma and seminoma, dysgerminoma, germinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16536313

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  3 in total

1.  Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.

Authors:  Ryan Ashkar; Darren R Feldman; Nabil Adra; Mohammad Abu Zaid; Samuel A Funt; Sandra K Althouse; Susan M Perkins; Christin I Snow; Kayla M Lazzara; Lina M Sego; David I Quinn; Nasser H Hanna; Lawrence H Einhorn; Costantine Albany
Journal:  Invest New Drugs       Date:  2021-05-24       Impact factor: 3.651

2.  The core four - A panel of immunohistochemistry markers to diagnose and subtype testicular germ cell tumors.

Authors:  V N Ranjitha; Rashmi Khemani; B Vishal Rao; Daphne Fonseca; S Sudha Murthy; Ashwin Giridhar; Y Jayakarthik; Rakesh Sharma; K V V N Raju; T Subramanyeshwar Rao; Challa Sundaram
Journal:  Urol Ann       Date:  2021-12-28

3.  Comparative immunohistochemical characterization of canine seminomas and Sertoli cell tumors.

Authors:  Chi-Ho Yu; Du-Na Hwang; Ji-Young Yhee; Jong-Hyuk Kim; Keum-Soon Im; Whan-Gook Nho; Young-Soo Lyoo; Jung-Hyang Sur
Journal:  J Vet Sci       Date:  2009-03       Impact factor: 1.672

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.